Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis

Abstract

Interferon-beta (IFNβ) reduces the number and load of new contrast-enhancing lesions (CELs) in patients with multiple sclerosis (MS). However, the ability of IFNβ to reduce lesion sizes and re-enhancements of pre-existing CELs has not been examined extensively. Activity of contrast re-enhancing lesions (Re-CELs) and contrast single-enhancing lesions (S-CELs) were monitored in ten patients with relapsingremitting (RR) MS. These patients underwent monthly post-contrast magnetic resonance imaging (MRIs) for an 18-month natural history phase and an 18-month therapy phase with subcutaneous IFNβ-1b, totaling 37 images per patient. The activity was analysed using the first image as a baseline and registering subsequent active monthly images to the baseline. There was a 76.4% reduction in the number of CELs with IFNβ therapy. The decrease was greater (P=0.003) for S-CELs (82.3%) than for Re-CELs (57.4%). S-CELs showed no changes in durations of enhancement and maximal lesion sizes with treatment. Exclusively for Re-CELs, IFNβ-1b significantly decreased maximal lesion sizes, total number of enhancement periods and total months of enhancement. Thus, IFNβ appears to be effective in reducing the degree of severity of inflammation among Re-CELs, as reflected by their reduced maximal lesion sizes and durations of enhancement.

Keywords

contrast-enhancing lesions interferon-beta lesion sizes magnetic resonance imaging multiple sclerosis re-enhancing lesions

Get full access to this article

View all access options for this article.

References

McDonald WI , Compston A , Edan G , Goodkin D , Hartung HP , Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis . Ann Neurol 2001; 50: 121-127 .

McFarland HF , Frank JA , Albert PS , Smith ME , Martin R , Harris JO et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis . Ann Neurol 1992; 32: 758-766 .

Miller DH , Barkhof F , Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis . Brain 1993; 116: 1077-1094 .

Bastianello S , Pozzilli C , Bernardi S , Bozzao L , Fantozzi LM , Buttinelli C et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis . Neurology 1990; 40: 591-595 .

Hawkins CP , Munro PM , MacKenzie F , Kesselring J , Tofts PS , du Boulay EP et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers . Brain 1990; 113: 365-378 .

Kermode AG , Thompson AJ , Tofts P , MacManus DG , Kendall BE , Kingsley DP et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications . Brain 1990; 113: 1477-1489 .

Harris JO , Frank JA , Patronas N , McFarlin DE , McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history . Ann Neurol 1991; 29: 548-555 .

Stone LA , Frank JA , Albert PS , Bash CN , Smith ME , Maloni H et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis . Ann Neurol 1995; 37: 611-619 .

McFarland HF , Barkhof F , Antel J , Miller DH. The role of MRI as a surrogate outcome measure in multiple sclerosis . Mult Scler 2002; 8: 40-51 .

10.

Pozzilli C , Bastianello S , Koudriavtseva T , Gasperini C , Bozzao A , Millefiorini E et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short-term study in relapsing-remitting multiple sclerosis . J Neurol Neurosurg Psychiatry 1996; 61: 251-258 .

11.

Filippi M , Rovaris M , Capra R , Gasperini C , Prandini F , Martinelli V et al. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology . J Neurol Neurosurg Psychiatry 1999; 67: 386-389 .

12.

Miller DH , Molyneux PD , Barker GJ , MacManus DG , Moseley IF , Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European study group on interferon-beta1b in secondary progressive multiple sclerosis . Ann Neurol 1999; 46: 850-859 .

13.

Brex PA , Molyneux PD , Smiddy P , Barkhof F , Filippi M , Yousry TA et al. The effect of IFNβeta-1b on the evolution of enhancing lesions in secondary progressive MS . Neurology 2001; 57: 2185-2190 .

14.

Barkhof F , Scheltens P , Frequin ST , Nauta JJ , Tas MW , Valk J et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity . AJR Am J Roentgenol 1992; 159: 1041-1047 .

15.

van Waesberghe JH , van Walderveen MA , Castelijns JA , Scheltens P , Lycklama a Nijeholt GJ et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR . AJNR Am J Neuroradiol 1998; 19: 675-683 .

16.

Ciccarelli O , Giugni E , Paolillo A , Mainero C , Gasperini C , Bastianello S et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis . Eur J Neurol 1999; 6: 455-459 .

17.

Filippi M , Rovaris M , Rocca MA , Sormani MP , Wolinsky JS , Comi G et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into ‘black holes’ . Neurology 2001; 57: 731-733 .

18.

Columba-Cabezas S , Serafini B , Ambrosini E , Aloisi F. Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation . Brain Pathol 2003; 13: 38-51 .

19.

Lehmann PV , Sercarz EE , Forsthuber TG , Dayan CM , Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire . Immunol Today 1993; 14: 203-208 .

20.

Brenchley JM , Douek DC , Ambrozak DR , Chatterji M , Betts MR , Davis LS et al. Expansion of activated human naïve T-cells precedes effector function . Clin Exp Immunol 2002; 130: 432-440 .

21.

Targoni OS , Baus J , Hofstetter HH , Hesse MD , Karulin AY , Boehm BO et al. Frequencies of neuroantigen-specific T cells in the central nervous system versus the immune periphery during the course of experimental allergic encephalomyelitis . J Immunol 2001; 166: 4757-4764 .

22.

Poser CM , Paty DW , Scheinberg L , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

23.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

24.

Panitch H , Goodin DS , Francis G , Chang P , Coyle PK , O’Connor P et al. Randomized, comparative study of inter-feron beta-1a treatment regimens in MS: the EVIDENCE trial . Neurology 2002; 59: 1496-1506 .

25.

Leary SM , Miller DH , Stevenson VL , Brex PA , Chard DT , Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial . Neurology 2003; 60: 44-51 .

26.

Medical Numerics, Inc. MEDx 3.42. Retrieved October 2004 from www.medicalnumerics.com

27.

Jenkinson M , Smith S. A global optimisation method for robust affine registration of brain images . Med Image Anal 2001; 5: 143-156 .

28.

Cohen MS , DuBois RM , Zeineh MM. Rapid and effective correction of RF inhomogeneity for high field magnetic resonance imaging . Hum Brain Mapp 2000; 10: 204-211 .

29.

Russ JC. The image processing handbook, first edition. Boca Raton: CRC Press , 1992.

30.

Rosner B. Fundamentals of biostatistics, fifth edition. Australia: Duxbury , 2000.

31.

Cotton F , Weiner HL , Jolesz FA , Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals . Neurology 2003; 60: 640-646 .

32.

Hiehle JF , Grossman RI , Ramer KN , Gonzalez-Scarano F , Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images . AJNR Am J Neuroradiol 1995; 16: 69-77 .

33.

Bruck W , Bitsch A , Kolenda H , Bruck Y , Stiefel M , Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology . Ann Neurol 1997; 42: 783-793 .

34.

Paolillo A , Bastianello S , Frontoni M , Gasperini C , Giugni E , Ciccarelli O et al. Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a . J Neurol 1999; 246: 443-448 .